Abstract | BACKGROUND: MATERIALS AND METHODS: A total of 415 female patients who presented to Duzce Public Hospital in 2011-2012 for AUB and who underwent EC were included. We determined the reasons for AUB, and females with hyperplasia were treated with 10 mg/day medroxyprogesterone acetate for 14 days/month or 160 mg/day megestrol acetate continuously for 3 months. We evaluated the efficacy of progestins for periods of three and/or six cycles by repeating EC. A statistical analysis of specific endometrial causes according to age of presentation was conducted using the chi-square test. RESULTS: Among the 415 females (average age, 53.5 years) followed for 6 months, 186 had physiological changes (44.8%), 89 had simple hyperplasia (21.44%), 1 had atypical hyperplasia (0.2%), 6 had (1.44%) complex hyperplasia, 3 had (0.72%) atypical complex hyperplasia, and 5 had adenocarcinoma (1.2%). Regression rates were 72.7-100%, and the optimum results were observed after 6 months of hormonal therapy. CONCLUSIONS: The main cause of AUB was physiological change. Progestin therapy resulted in significant regression even in females with atypical hyperplasia.
|
Authors | Simender Mesci-Haftaci, Handan Ankarali, Ali Yavuzcan, Mete Caglar |
Journal | Asian Pacific journal of cancer prevention : APJCP
(Asian Pac J Cancer Prev)
Vol. 15
Issue 8
Pg. 3737-40
( 2014)
ISSN: 2476-762X [Electronic] Thailand |
PMID | 24870785
(Publication Type: Journal Article)
|
Chemical References |
- Medroxyprogesterone Acetate
|
Topics |
- Adenocarcinoma
(complications, diagnosis, pathology)
- Adult
- Aged
- Aged, 80 and over
- Curettage
(methods)
- Endometrial Hyperplasia
(complications, drug therapy, pathology)
- Endometrial Neoplasms
(complications, diagnosis, pathology)
- Endometrium
(pathology)
- Female
- Humans
- Medroxyprogesterone Acetate
(therapeutic use)
- Middle Aged
- Treatment Outcome
- Uterine Hemorrhage
(diagnosis, etiology, pathology)
- Young Adult
|